Menu Search
Equities

Solvonis Therapeutics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
J4I:STU

Solvonis Therapeutics PLC

Actions
  • Price (EUR)0.002
  • Today's Change0.001 / 33.33%
  • Shares traded0.00
  • 1 Year change0.00%
  • Beta1.7438
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Solvonis Therapeutics PLC is a clinical-stage biotechnology company developing treatments for addiction and mental health disorders. The Company is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need. It is focused on Alcohol Use Disorder (AUD), which affects over 40 million people across the United States, United Kingdom, and EU4 markets, and Post-Traumatic Stress Disorder (PTSD), impacting more than 13 million adults in the United States and approximately 20 million across those same regions. AUD is characterized by compulsive, harmful drinking, and is associated with significant health risks, including chronic diseases, mental health conditions and accidents, injuries and violence. PTSD is a complex and debilitating mental health condition that develops in some people who have experienced traumatic events, for example violence, an accident, war or a natural disaster.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-2.60m
  • Incorporated2017
  • Employees--
  • Location
    Solvonis Therapeutics PLC25 Eccleston PlaceLONDON SW1W 9NFUnited KingdomGBR
  • Websitehttps://solvonis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.